| Jun 3 |
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
|
| May 31 |
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
|
| May 24 |
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
|
| May 21 |
Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
|
| May 21 |
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
|
